Last reviewed · How we verify
Miltefosine , meglumine antimoniate
At a glance
| Generic name | Miltefosine , meglumine antimoniate |
|---|---|
| Sponsor | Centro de Investigaciones Bioclínicas de la Fundación Fader |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Randomised Clinical Trial for New Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan (PHASE3)
- Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New World (PHASE3)
- Treatment of Mucosal Bolivian Leishmaniasis (PHASE3)
- The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil (PHASE2)
- Study of Cases of Cutaneous Leishmaniasis Treated With Miltefosine in French Guiana, Retrospective Study
- Miltefosine and GM-CSF in Cutaneous Leishmaniasis (PHASE3)
- Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia. (PHASE3)
- Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: